Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BI 695500 (Rituximab Biosimilar) in Rheumatoid Arthritis Extension
NCT01955733Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2013
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of MabionCD20 in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Started May 2013; status: terminated.
02
Drugs
MabionCD20
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01955733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01955733.